Study: NTRK fusions are far more frequently seen in pediatric tumors
In a large study of pediatric cancer patients, researchers from Children's Hospital of Philadelphia have analyzed the frequency, fusion partners, and clinical outcome of neurotrophic tyrosine receptor kinase (NTRK) fusions, which are clinical biomarkers that identify patients suitable for treatment with FDA-approved TRK inhibitors.